Dr. Luke on the FDA Approval of Adjuvant Nivolumab in Melanoma
Jason J. Luke, MD
Published: Wednesday, Dec 20, 2017
Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.
SELECTED LANGUAGE
Jason J. Luke, MD, assistant professor of medicine, University of Chicago Medicine, discusses the FDA approval of nivolumab (Opdivo) to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.